Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...

We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and technical operations across modalities, specifically in allogenic cell ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

The global Oncolytic Virus Cancer Therapy (OVT) market is expected to be valued at USD 22.86 million in 2023, with ...

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low-density lipoprotein (LDL) ...